Dr. Shashi Kori

Dr. Shashi Kori is a Neurologist and Neuro-Oncologist trained at Sloan Kettering Cancer Center and Cornell University. He founded and served as Vice Chairman of the Department of Neurology at University of South Florida as well as Director of Pain and Palliative Care at Duke University. Dr. Kori has more than 110 publications, served on editorial boards of many professional journals as well as national and international conferences and task forces. In addition, he has over 2 decades of experience in the drug development industry including GSK, Allergan, and MAP Pharmaceuticals.  Dr. Kori’s vast knowledge of the research, medical and pharmaceutical industries has provided Novilla with the foundation to unlock key therapies for high impact indications. His passion for improving the quality of life for major disease populations has been the catalyst for Novilla’s pipeline which seeks to improve millions of lives.

Patents and Publications

  • ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE PARTICLES USING A METERED DOSE INHALER

    Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90<5.0 micron volumetric median diameter.

  • MANAGEMENT OF BONE PAIN SEONDARY TO METASATIC DISEASE

    Metastatic involvement of the bone is one of the most common causes of pain in cancer patients. ' Of the eximated 1.4 million patients who will be newly diagnosed with cancer in the United States this vear. 30% to 70% will develop skeletal metastases 4.3 The most common primary malienancies that metastasize to the bone are breast. kidney, lung, and prostate (Table 1).* The most common sites of metastasis are the vertebrac, pelvis, and long bones (Table 2). Pain is the most frequent symptom of bone metastases and develops cradually over weeks to months, becoming progressively more severe. Pain combined with other complications (eg. hypercalcemia, pathologic fracture, nerve root compression, spinal cord compression, focal neurologic deticits, and forced immobilization) can lead to a decrease in patients' quality of life. Palliation of symptoms can result in significant restoration of quality of life for these patients. Such palliation measures, when possible, should avor additional discomfort to patients and be cost chiective and simile tondminister. Tne provosed algonthm on emporasis on me mussaiscipanary leam effort

  • METHOD OF REMOTELY CONTROLLING PAIN

    Disclosed are methods for a novel, counter-intuitive, non-obvious, non-invasive, simple to administer, non-systemic delivery of analgesics through the skin to the DRG and DH area to block and relieve pain in the dermatomal distribution of that particular DRG. This method of pain control provides a non-addictive, inexpensive, simple to use alternative to the present standard of care involving addictive, potentially dangerous opioid therapy.